Adjuvanted RSVPreF3 vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Cardiovascular DiseaseRespiratory Syncytial Virus Infections

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

1

Geodon

Pfizer

Approved

—2

Cardene

Sun Pharmaceutical Industries, Inc.

Approved

—3

Primacor

Sanofi

Approved

—4

Giapreza

LLa Jolla Pharmaceutical Company

Approved

—5

Midamor

PPadagis LLC

Approved

—6

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—8

Colcrys

Jazz Pharmaceuticals

Phase 3

19

Cagrilintide

Novo Nordisk

Phase 3

110

Pelacarsen

Novartis

Phase 3

1Show 45 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immune Response1 trial

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Completed·GSK·Phase 1/2·NCT00698490·130 enrolled

Influenza1 trial

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

Completed·GSK·Phase 3·NCT00319098·5,075 enrolled

Respiratory Syncytial Virus Infections1 trial

A Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)

Active, not recruiting·GSK·Phase 2·NCT07092865·168 enrolled

Cardiovascular Disease1 trial

A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Above Who Are at Risk for Cardiovascular Events

Not yet recruiting·GSK·Phase 2·NCT07712380·450 enrolled

Details

Drug Info

Related News